Iskra was appointed Executive Vice-President (EVP), Vaccines & Immune Therapies Unit in November 2021, and is responsible for leading all COVID-19 therapy area activities, including R&D, commercial, medical, as well as AstraZeneca’s global infectious disease teams. Prior to this role, Iskra was EVP for the Europe & Canada region (for which she retains responsibility until the announcement of a successor) and has been a member of AstraZeneca’s Senior Executive Team (SET) since 2017.

Having trained as a Doctor of dental medicine at the Medical University of Zagreb, Croatia, Iskra joined AstraZeneca in 2001. During this time, Iskra has held a variety of in-market, regional sales and marketing and general management roles, including Head of Specialty Care, Central & Eastern Europe, Middle East and Africa.

In 2012 she joined AstraZeneca Russia as Marketing Director, before being appointed General Manager in 2014. Subsequently, in 2016 Iskra was made Area Vice-President for Russia and Eurasia, before her appointment as EVP, Europe in April 2017, and the later expansion of this role to Europe & Canada in 2019.

Iskra has an International Executive MBA in Business and Leadership from the IEDC-Bled School of Management, Slovenia.